Gossamer Bio’s 1-for-80 reverse stock split became effective at 11:59 p.m. Eastern time on Sept. 10, 2026, with split-adjusted trading set to begin at market open on Sept. 11 under the ticker “GOSS.”
The company’s common stock was combined so that every 80 shares outstanding before the split became 1 share after it. To handle fractional amounts, Gossamer said it will round up to the nearest whole share for holders entitled to a fraction, including positions held through DTC at the participant level.
The split also triggered proportional adjustments to several capital structure items: Outstanding convertible notes, including the 5.00% convertible senior notes due 2027 and the 7.50% convertible senior secured first lien notes due 2030 Warrants and prefunded warrants, along with their exercise prices Outstanding equity awards under the company’s equity incentive plans, including exercise prices Shares reserved for future issuance under the equity plans
The company’s authorized common stock count was cut sharply, from 4.0 billion shares to 50 million shares. Total authorized capital stock fell from 4.07 billion shares to 120 million shares.
Gossamer said the split is aimed at helping it regain compliance with Nasdaq’s minimum bid price rule. The stock must close at at least $1.00 for 10 consecutive business days before the Oct. 5, 2026 compliance date.
The split did not change the par value of the common stock, and stockholders’ ownership percentages and voting power remained the same apart from fractional-share effects. As a result of these announcements, the company's shares have moved -6.43% on the market, and are now trading at a price of $10.6595. For more information, read the company's full 8-K submission here.
